Jason Pickett Power - 14 Apr 2025 Form 3 Insider Report for AVANOS MEDICAL, INC. (AVNS)

Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
29 Apr 2025, 15:45:04 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Mojirade James, as attorney-in-fact for Jason Pickett pursuant to Power of Attorney filed herewith

Key filing fact

Jason Pickett Power filed Form 3 for AVANOS MEDICAL, INC. (AVNS) on 29 Apr 2025.

Key facts

  • This page summarizes Jason Pickett Power's Form 3 filing for AVANOS MEDICAL, INC. (AVNS).
  • 0 reported transactions and 5 derivative rows are listed below.
  • Accepted by SEC: 29 Apr 2025, 15:45.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AVNS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
40,113
Date
14 Apr 2025
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVNS holding Derivative

Employee Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
14 Apr 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,174
Exercise price
$29.48
Footnotes
F2
AVNS holding Derivative

Employee Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
14 Apr 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,670
Exercise price
$36.74
Footnotes
F3
AVNS holding Derivative

Employee Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
14 Apr 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,278
Exercise price
$52.10
Footnotes
F4
AVNS holding Derivative

Employee Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
14 Apr 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,509
Exercise price
$43.59
Footnotes
F5
AVNS holding Derivative

Employee Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
14 Apr 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,182
Exercise price
$28.87
Footnotes
F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Of these shares, 28,476 are represented by time-based restricted share units (TRSUs) awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended. These TRSUs will vest as follows: (i) 16,300 on April 22, 2026; (ii) 2,496 on May 6, 2026; (iii) 1,510 on May 6, 2027; (iv) 2,696 on May 7, 2026; (v) 2,696 on May 7, 2027; and (vi) 2,778 on May 7, 2028. Each TRSU is the economic equivalent of one share of Common Stock.

Footnote F2

These options vested 30% on May 5, 2017, 30% on May 5, 2018, and 40% on May 5, 2019.

Footnote F3

These options vested 30% on May 3, 2018, 30% on May 3, 2019, and 40% on May 3, 2020.

Footnote F4

These options vested 30% on May 3, 2019, 30% on May 3, 2020, and 40% on May 3, 2021.

Footnote F5

These options vested 30% on May 8, 2020, 30% on May 8, 2021, and 40% on May 8, 2022.

Footnote F6

These options vested 30% on May 7, 2021, 30% on May 7, 2022, and 40% on May 7, 2023.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .